See you next year in Calgary!

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Wednesday, April 10, 2024

}

07:00 – 19:00

North Tower

- Junior Ballroom Foyer

Conference Registration

}

07:00 – 18:00

North Tower

- Junior Ballroom Foyer

Internet Café

}

07:00 – 18:00

North Tower (lower lobby)

- Gulf Island A

Speaker Ready Room

}

07:00 – 18:00

B Tower

- Beluga

Sponsor Lounge – BD

}

07:00 – 18:00

B Tower

- Blue Whale

Sponsor Lounge – DiaSorin

}

07:00 – 18:00

South Tower (4th floor)

- Columbia

Sponsor Lounge – bioMérieux

}

07:00 – 18:00

North Tower

- Parksville

Escape Room

07:00 - 17:00
Sign Up (last group entrance 17:00)
}

07:00 – 08:45

North Tower (4th floor)

- Port McNeill

AMMI Canada AGM and Sections Meeting

07:00 - 07:30
Breakfast
07:30 - 08:45
Meeting
}

09:00 – 09:30

North Tower

- Grand Ballroom BC

Welcome and Opening of Conference

Agatha Jassem (BC) and Deb Yamamura (ON)

}

09:30 – 11:00

North Tower

- Grand Ballroom BC

Plenary

Very Bad Bugs Yet So Few Drugs (in Canada)

MODERATORS:
Prameet Sheth (ON)
Philippe Lagacé-Wiens (MB)

SPEAKERS:
Andrew Morris (ON)
Alfred Gin (MB)

At the end of this session, participants should be able to:

  • Review the state of Multi-Drug Resistant (MDR) organisms in Canada
  • Explain new drugs available worldwide
  • Describe the challenges and solutions to bringing in new drugs to Canada
}

11:00 – 20:00

North Tower

- Pavilion Ballroom and Junior Ballroom

Exhibit Hall Open / Poster Viewing

}

11:00 – 11:30

North Tower

- Pavilion Ballroom and Junior Ballroom

Break

}

11:30 – 12:30

North Tower

- Grand Ballroom A

Changing Resistance Epidemiology of Gram-negative Pathogens:
Are Current Empiric Antibiotic Choices Adequate?

(co-developed learning activity, pre-registration required to maximum of 150 participants)

MODERATOR:
Ramzi Fattouh (ON)

SPEAKERS:
Victor Leung (BC)
Kevin Schwartz (ON)

At the end of this session, participants should be able to:

  • Describe the adequacy of current empiric treatment choices for serious gram-negative infections
  • Identify advantages and disadvantages of current available therapies (including combos) for serious infections due to MDR gram-negative infections
  • Understand the consequences of late effective therapy in the management of serious gram-negative infections, including the impact on patient outcomes and healthcare costs
  • Review the principles and considerations of de-escalation for serious gram-negative infections

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Merck Canada and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

11:30 – 12:30

North Tower

- Grand Ballroom D

Long-Acting Lipoglycopeptides: Where Do They Fit in the Contemporary Treatment of Infections?

(co-developed learning activity, pre-registration required to maximum of 150 participants)

MODERATOR:
William Connors (BC)

SPEAKERS:
Michael Silverman (ON)
George Sakoulas (CA)

At the end of this session, participants should be able to:

  • Describe the class of lipoglycopeptides and summarize their unique pharmacodynamics and pharmacokinetics and microbiological coverage
  • Discuss the role of lipoglycopeptides in the treatment of infections for both on-label and off-label indications and safety data
  • Describe the experience of operationalizing the use of lipoglycopeptides in Canada and the United States

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Paladin Canada and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

12:30 – 14:00

North Tower

- Pavilion Ballroom and Junior Ballroom

Lunch in Exhibit Hall

}

12:45 – 13:45

North Tower

- Pavilion Ballroom and Junior Ballroom

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Poster Presenters at Posters to Answer Questions

 

WP001 (#11) WITHDRAWN
WP002 (#64) Antimicrobial Stewardship Quality Improvement Intervention for
Enterococcus bacteremia
Presenting: Irina Rajakumar
WP003 (#72) Evaluating the feasibility of a reflex testing algorithm for Neisseria gonorrhoeae culture and NAAT co-testing requests
Presenting: Mihaela Serbanescu
WP004 (#90) Characterization of daptomycin use in leukemia bone marrow transplantation, intensive care, and solid organ transplant patients at a Canadian tertiary hospital
Presenting: Alyssa Azote
WP005 (#104) Crafting Double Drug Antibiograms for Enhanced Antimicrobial Precision
Presenting: Connie Xie
WP006 (#116) Evaluation of antibiotic prophylaxis for peri-operative infections in vascular surgery: A retrospective analysis at Vancouver General Hospital
Presenting: Nakyung Kim
WP007 (#119) Guideline adherence of antibiotic prescriptions for urinary tract infections in a paediatric emergency department
Presenting: Alino Demean Loghin
WP008 (#152) S. aureus skin and soft tissue (SSTI) isolate sensitivities in northern Manitoba and north-western Ontario communities seen in the context of empiric therapeutic decision making
Presenting: Kelly MacDonald
WP009 (#168) Improving aminoglycoside resistance surveillance and stewardship efforts through nomenclature harmonization with the Comprehensive Antibiotic Resistance Database
Presenting: Brian Alcook
WP010 (#184) Bridging the Gap: Unveiling the crucial cole of Mycobacterium antibiograms in antimicrobial precision
Presenting:  Connie Xie
WP011 (#22) Implementation of an antimicrobial stewardship intervention to improve management of bacteriuria and candiduria in hospitalized adults
Presenting: Emily Black
WP012 (#302) Decreasing antibiotic use in infants is correlated with a declining asthma incidence rate at the population level, 2000-2019
Presenting: Erica Chuang
WP013 (#367) The impact of CLSI M100E33 Enterobacterales aminoglycoside breakpoint changes
on available treatment options for β-lactamresistant organisms in Canada
Presenting:  Ellen Avery
WP014 (#10) In-vitro antibacterial activity of some plant infusions against biofilm-forming methicillin-resistant Staphylococcus aureus
Presenting: Tesleem Ibrahim
WP015 (#16) Antimicrobial susceptibility of Neisseria gonorrhoeae isolates in Yaoundé, Cameroon
Presenting: Carolle Tayimetha
WP016 (#40) Off-label use of dalbavancin to improve treatment outcomes and reduce healthcare costs: a single-center quality improvement initiative
Presenting: Adrianna Gunton
WP017 (#102) Phage Science, Therapeutics, and Research: The Public Health Agency of Canada’s New Phage Therapy Program
Presenting: Michael Parcey
WP018 (#133) WITHDRAWN
WP019 (#142) Ceftobiprole usage in Canada: Final results from the CLEAR Registry
Presenting: Melanie Baxter
WP020 (#150) Treating hospital-acquired, ventilated hospital-acquired and ventilatory associated bacterial pneumonia in Canada with ceftolozane/tazobactam (C/T): Final Results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry
Presenting: Melanie Baxter
WP021 (#156) How and why clinicians use IV fosfomycin in Canada: Results from the national CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry
Presenting: Melanie Baxter
WP022 (#163) IV dalbavancin usage in Canada: Results from the CLEARRegistry
Presenting: Melanie Baxter
WP023 (#164) In vitro activity of cefditoren, a new-to-Canada oral third-generation cephalosporin, against community-acquired respiratory tract, skin/soft tissue, and urinary tract infection pathogens isolated from Canadian patients: CANWARD 2015-2020
Presenting: Melanie Baxter
WP024 (#173) Phage therapy in the management of urinary tract infections: A comprehensive systematic review
Presenting: Jonathan Cook
WP025 (#200) A replica plating method for efficient, high-throughput screening of antibiotic
gene clusters in bacteria uncovers a holomycin-like cluster in the clinical isolate, Pantoea agglomerans 20KB447973
Presenting: Ashlyn Kirk
WP026 (#231) Epidemiology of Streptococcus pneumoniae serotypes 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B causing invasive pneumococcal disease (IPD) in Canada: Coverage of V116, a new 21-valent conjugate pneumococcal vaccine in the SAVE Study, 2018-2021
Presenting: John Schellenberg
WP027 (#235) Comparison of PCV-20 and PPSV-23 vaccine coverage of Streptococcus pneumoniae (SPN) serotypes in Canada: The SAVE Study, 2018-2021
Presenting: John Schellenberg
WP028 (#285) A novel data structure for prediction of phenotypic antimicrobial resistance based
on whole-genome sequencing
Presenting: Donald Brody Duncan
WP029 (#339) Assessment of hybrid assembly methods for accurate plasmid reconstruction
in carbapenemase-producing organisms
Presenting: Adriana Cabrera Delgado
WP030 (#95) Does increased vancomycin MIC increase the risk of complications in patients
with methicillin sensitive Staphylococcus aureus blood stream infections?
A retrospective review
Presenting: Alexis Donovan
WP031 (#95) Virulence factors and cellular interactions of Staphylococcus aureus in Bovine mammary epithelial cells
Presenting: Erika Bonsaglia
WP032 (#98) Characterization of enterotoxin-producing S. aureus isolated from the hands
and nose of food handlers
Presenting: Ivana Castilho
WP033 (#99) Adhesion and invasion in Mac-T cells by Escherichia coli isolated from cows
with clinical mastitis
Presenting: Stéfani Dantas
WP034 (#209) Reducing false positivity rates of Neisseria gonorrhoeae nucleic acid amplification testing using a two-stage molecular testing algorithm in a low prevalence population
Presenting: Matthew Spear
WP035 (#272) Genomic analysis of environmental and clinical isolates of Vibrio parahaemolyticus collected from 1999 to 2022 in the Pacific Coast
Presenting: John Palmer
WP036 (#275) Antimicrobial susceptibility patterns of Viridans Group Streptococci in a
Canadian tertiary care centre
Presenting: Sonya Ramondino
WP037 (#290) Evaluation of the use of a Vitek MS MALDI research database in the identification of rare bacterial species in a clinical laboratory
Presenting: Julia MacIsaac
WP038 (#299) Transmission dynamics and genotypic diversity of Mycobacterium tuberculosis
in Colombian persons deprived of liberty
Presenting: Ashley Heilmann
WP039 (#328) A visual job aid improves filling of adult blood culture bottles in
emergency departments
Presenting: Clayton Hall
WP040 (#337) Virulence factors in Staphylococcus aureus obtained from chronic venousulcers
Presenting: Stéfani Dantas
WP041 (#350) Assessing the risk of Mycobacterium tuberculosis transmission by
tissue transplantation
Presenting: Amaury Gaussen
WP042 (#66) Enhanced Caenorhabditis elegans in vivo Infection model for screening new antimicrobial compounds against Gram-positive and Gram-negative bacteria
Presenting: Salman Mirza
WP043 (#241) Improved spore recovery from clinical samples for metagenomic sequencing
Presenting: Gillian Tanabe
WP044 (#308) A non-human primate model of human coronavirus HCoV-22E recapitulates aspects
of respiratory disease observed in humans
Presenting: Maedeh Naghibosadat
WP045 (#38) WITHDRAWN
WP046 (#85) Four-week HCV prophylactic antiviral strategy for HCV-viremic donors to HCV negative kidney transplant recipients
Presenting: Yahya Shabi
WP047 (#134) The effect of antiplatelet agents on end organ dysfunction and mortality in community acquired pneumonia: A systematic review and meta-analysis
Presenting: Lana Tennenhouse
WP048 (#137) ‘It’s welcoming there’: a qualitative analysis evaluating a community-based skilled nursing facility that supports patients with substance use disorders complete antibiotic therapy for severe bacterial infections
Presenting: Yousef Shahin
WP049 (#190) Donor diversity in fecal microbiota transplantation: microbial composition differences in donor stool microbiomes
Presenting: Ceylon Simon
WP050 (#216) Factors associated with a positive urine culture in paediatric patients with a diagnosis of urinary tract infections in the emergency department
Presenting: Brandon Noyon
WP051 (#222) Factors affecting adverse events in immunocompromised patients
with Pneumocystis pneumonia
Presenting: Poramed Winichakoon
WP052 (#254) Treatment of drug resistant tuberculosis with bedaquiline, pretomanid, linezolid +/- moxifloxacin (BPaL/M): Feasibility and implementation challenges in Western Canada
Presenting: Paige Muir
WP053 (#257) Salmonella septic arthritis and osteomyelitis in patients receiving tumour necrosis factor alpha inhibitors
Presenting: Shahrukh Towheed
WP054 (#259) Clinical characteristics and demographics of patients experiencing methicillin sensitive Staphylococcus aureus bacteremia as a function of high inoculum cefazolin resistance – a population-based multi-year study
Presenting: Alexander Kipp
WP055 (#271) Septic Bursitis: Insights from a Canadian Single-Center Study
Presenting: Reza Rahimi Shahmirzadi
WP056 (#22) Long COVID and associated factors among Chinese immigrants in Canada
Presenting: Peizhong Pete Wong
WP057 (#50) Optimal Specimens for SARS-CoV-2 testing appear to vary depending on the predominant Variant of Concern (VOC)
Presenting: Justin Callahan
WP058 (#94) Clinical practice guideline-supported administration of monoclonal antibody therapy for high-risk patients with COVID-19: experience of a quaternary care center
Presenting: Keely Hammond
WP059 (#110) Assessing COVID-19 bivalent vaccine uptake and associated factors among
Canadian Chinese
Presenting: Peizhong Pete Wong
WP060 (#135) Evaluation of a protocol for managing the cyclosporine and nirmatrelvir/ritonavir drug-drug interaction in kidney transplant recipients
Presenting: Kyla Agtarap
WP061 (#136) Exploring the effects of vitamin D on COVID-19 infection, disease severity,
and long-COVID
Presenting: Peizhong Wang
WP062 (#161) Monitoring of SARS-CoV-2 variants in wastewater using whole genome sequencing
Presenting: Linnet Immaraj
WP063 (#244) Performance of IgA and IgG antibodies in the serological classification of recent SARS-CoV-2 infections among pregnant individuals
Presenting: Guadalein Tanunliong
WP064 (#331) COVID-19 non-severe therapy consult service: reflections on a hub and spoke model
Presenting: Tasha Ramsey
WP065 (#351) Public acceptability of rapid COVID self-testing: Insights from a community embedded implementation project
Presenting: Barbara Goodall
WP066 (#356) Care framework for individuals at risk of and experiencing persistent COVID-19
Presenting: Lisa Barrett
WP067 (#371) PLOVER: A novel data system for province-wide lab test aggregation, public health response, and outbreak investigations by whole genome sequencing
Presenting: Chris Fjell
WP068 (#279) Global Clinical Phage Rounds (G-CPR), an international collaborative educational forum addressing patient cases treated with bacteriophage therapy
Presenting: Greg German
WP069  WITHDRAWN
WP070 (#181) Genomic relationships between environmental and clinical Vibrio parahaemolyticus isolates in Canada
Presenting: John Palmer
WP071 (#102) Pre-treatment Drug Resistance of Human Immunodeficiency Virus type 1 Subtypes
in HIV Patients in Ghana: A Cross-Sectional Study
Presenting: Darius Quansah
WP072 (#186) Evaluation of dried blood spot testing among HIV-1 viral controllers with the Roche COBAS Ampli Prep/COBAS TaqMan HIV-1 Qualitative Test, version 2.0 (HI2QCAP)
Presenting: Farzan Pavri
WP073 (#297) A global perspective: the gene expression profile of tuberculosis disease among people living with HIV
Presenting: Erwin Taguiam
WP074 (#316) Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV-infected individuals: evidence for long-term efficacy
Presenting: Brian Conway
WP075 (#23) Multiple antibiotic resistance tracing by plasmid profile analysis of bacteria isolates from medical dump bin
Presenting: Ronke Adeniyi
WP076 (#30) Candida auris outbreak associated with patients with sars-cov-2 in the intensive care unit of a high-complex hospital in the city of Cúcuta, Colombia
Presenting: Andres Gonzalez
WP077 (#84) Burkholderia cepacia ST 767 causing a three years nosocomial outbreak in a hemodialysis unit
Presenting: Vera Rall
WP078 (#109) Genetic epidemiology of invasive Serratia isolates in a tertiary hospital system: insights from whole-genome sequencing
Presenting: Adam Komorowski
WP079 (#122) Carbapenamase-producing Enterobacterales (CPE) in patient sink and shower drains
Presenting: Jennifer Tat
WP080 (#127) Prevalence of intestinal parasites and associated risk factors among Debre Genet Primary School students, Naeder Adiet District, Tigray, Ethiopia
Presenting: Teklemichael Gebremariam
WP081 (#131) Comparison of the efficacy of povidone-iodine solution with intranasal mupirocin ointment in decolonizing Staphylococcus aureus from the nasal cavity of healthcare workers: A single-blind randomized controlled trial
Presenting: Sara Abolghasemi
WP082 (#139) Surveillance for healthcare-associated infections and antimicrobial resistant organisms in Canadian long-term care homes: A cross-sectional survey
Presenting: Jessica Bartoszko
WP083 (#143) Seasonal trends in incidence and in-hospital mortality of hospitalization due to
all-cause community acquired pneumonia (CAP) and pneumococcal CAP (pCAP)
in Canada, 2009-2019
Presenting: Gokul Raj Pullagura
WP084 (#160) Evaluating Copper-Coated Surfaces in a Tertiary Care Paediatric Hospital: Effects
on Microbial Load and Healthcare-Associated Infections
Presenting: Jocelyn Srigley
WP085 (#176) Estimation of the Incidence of Provincial Healthcare-Acquired COVID-19 Infection
Presenting: Yosuf Kaliwal
WP086 (#185) Navigating the threat of carbapenemase-producing organisms: Time-series analysis of a public health surveillance initiative from 2014-2022
Presenting: Aidan Nikiforuk
WP087 (#210) Launching a provincial acute care respiratory illness surveillance system
Presenting: Md Sabbir Hossain
WP088 (#260) Pneumocystis pneumonia outcomes in patients with immunocompromising conditions: a population-based study over 20 years (2002-2022) in one
Canadian province
Presenting: Carson Lo
WP089 (#276) Role of high-efficiency particulate air purifier in improvement of air quality and effective removal of indoor air contaminants at long-term healthcare facilities
Presenting: Ahlia Shaik
WP090 (#304) Whole genome sequencing of ten Enterobacter hormaechei revealed widespread transmission of blaKPC-3through two modes of transmission
Presenting: Florence Doualla-Bell
WP091 (#318) Shining a light on surgical site prevention: Nasal Photodis infection to prevent
SSI in Cardiac Surgery
Presenting: Stephanie Smith
WP092 (#360) Characterizing the gap in vaccination status in older adults residing in complex continuing care in an urban hospital
Presenting: Sharon Sukhdeo
WP093 (#74) Verification, analytical sensitivity, cost-effectiveness, and comparison of four
Candida auris screening methods
Presenting: Adam Komorowski
WP094 (#274) Impacts of COVID-19 on Invasive Fungal Infections in Canadian ICU Populations
Presenting: Erin Heifetz
WP095 (#273) Prevalence of laboratory confirmed Creutzfeldt-Jakob Disease from three Ontario Tertiary Care Centers between 2012-2022
Presenting: Kayla Gaete
WP096 (#162) Ancient cesspit contents reveal evidence for human parasite infections in
15th–16th century Bruges, Belgium
Presenting: Marissa Ledger
}

14:00 – 15:00

North Tower

- Grand Ballroom A

Masterclass A

AMR Genomics

(pre-registration required to maximum of 150 participants)

MODERATORS:
Catherine Hogan (BC)
Jessica Forbes (ON)

SPEAKERS:
Sam Chorlton (BC)
David Alexander (MB)

At the end of this session, participants should be able to:

  • Understand current landscape of genomics testing options for AMR prediction
  • Learn about the latest technologies available and analyses that can be performed for AMR prediction
  • Understand real-world examples showcasing utility and current limitations
}

14:00 – 15:00

North Tower

- Grand Ballroom D

Masterclass F

Viral Hepatidities

(pre-registration required to maximum of 150 participants)

MODERATORS:
Vanessa Meier-Stephenson (AB)
Agatha Jassem (BC)

SPEAKERS:
Jordan Feld (ON)
Ed Tam (BC)

At the end of this session, participants should be able to:

  • Describe how diagnostic screening and new therapies are changing the way Hep B is identified and managed in Canada
  • Identify new strategies and challenges to HCV elimination in Canada and highlight trials that are addressing these issues
}

15:00 – 15:15

North Tower

- Grand Ballroom Foyer

Break

}

15:15 – 16:15

North Tower

- Grand Ballroom A

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Oral Presentations Session A (student competition)

Moderator: Danielle Brabant-Kirwan (ON)

15:15 – 15:30
A01 (#363)
Healthcare Resource Use for Acute Respiratory Syncytial Virus Paediatric Hospitalization in Canadian infants: Immunization Monitoring Program ACTive (IMPACT) analysis
Presenting: Nirma Khatri Vadlamudi
15:30 – 15:45
A02 (#54)
Clinical significance of cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus (MSSA) infections: a systematic review
Presenting: Ashwin Sritharan
15:45 – 16:00
A03 (#228)
Rapid detection models of antifungal resistance in the pathogenic mold,
Aspergillus fumigatus using clinical MALDI-TOF mass spectrometry data
Presenting: Veronica Thorn
16:00 – 16:15
A04 (#296)
Designing a multiplex typing PCR assay for assessing in-hospital outbreaks of Clostridioides difficile
Presenting: Sheridan Baker
}

15:15 – 16:15

North Tower

- Grand Ballroom D

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Rapid Fire Presentations Sessions A

Moderator: William Connors (BC)

15:15 – 15:20
RFA01 (#27)
Increased rates of laboratory confirmed cases of syphilis in Western Canadian vs Eastern Canadian blood donors: 2022-2023
Presenting: Steven Drews
15:20 – 15:25
RFA02 (#88)
Sample processing methodology alters observed diversity in metagenomic and metatranscriptomic microbiome profiles from human stool
Presenting: Molly Pratt
15:25 – 15:30
RFA03 (#174)
Optimizing methods for the genomic surveillance of viral pathogens in wastewater
Presenting: Ian Restall
15:30 – 15:35
RFA04 (#191)
Molecular epidemiology of rotavirus strains in Quebec from January to June 2023
Presenting: Maude Paquette
15:35 – 15:40
RFA05 (#68)
Prevalence of antibodies to human t-cell lymphotropic virus-1/2 in Canada over thirty-three years of monitoring in blood donors
Presenting: Sheila O’Brian
15:40 – 15:45
RFA06 (#141)
Assessing the potential for specimen pooling to streamline nosocomial surveillance of methicillin resistant Staphylococcus aureus (MRSA)
Presenting: Mohammed Alqatani
15:45 – 15:50
RFA07 (#182)
Applying whole genome approaches to identify and resolve influenza A outbreaks in humans and animals
Presenting: Shannon Russell
15:50 – 15:55
RFA08 (#183)
Epidemiology and clinical characteristics of severe malaria in Canada, 2014-2022
Presenting: Mireille Desroches
15:55 – 16:00
RFA09 (#295)
Emergence of a novel FRI-type carbapenemase (blaFRI -12) in Enterobacter cloacae complex located on a novel IncR plasmid isolated in Canada
Presenting: Laura Mataseje
16:00 – 16:05
RFA10 (#370)
Association between use of a voluntary isolation centre and transmission of SARS – CoV -2: a matched cohort study of households
Presenting: Kevin Brown
16:05 – 16:10
RFA11 (#309)
A Comprehensive Risk Assessment Algorithm -guided SARS CoV -2 Vaccine Composition Strategy
Presenting: Victor Kramer
16:10 – 16:15
RFA12 (#312)
FluViewer: an automated bioinformatic pipeline for generating influenza A virus consensus genomes regardless of viral subtype or host
Presenting: Kevin Kuchinski
}

16:15 – 16:30

North Tower

- Grand Ballroom Foyer

Break

}

16:30 – 17:30

North Tower

- Grand Ballroom BC

State of the Art (START) Lecture

Zoonotic Diseases in Canada from a One Health Lens

MODERATOR:
Catherine Hogan (BC)
Philippe Lagacé-Wiens (MB)

SPEAKERS:
Katherine Plewes (BC)
David Waldner (AB)

At the end of this session, participants should be able to:

  • Summarize surveillance data on animal populations and the relationship with human disease
  • Explain how animal migration, importation and human factors introduce, maintain and spread zoonotic diseases in Canada
  • Describe the main diagnostic methods available for zoonotic diseases in Canada
}

17:30 – 18:15

North Tower

- Grand Ballroom BC

Special Lecture

Communications in Crisis, A Fireside Chat

MODERATOR AND PANELIST:
Ian Hanomansing (BC)

PANELISTS:
Zain Chagla (ON)
Angela Rasmussen (SK)
Lynora Saxinger (AB)

}

18:15 – 20:00

North Tower

- Pavilion Ballroom and Junior Ballroom

Welcome and Recognition Reception